AU2010217160C1 - Method for detecting metastasis of GI cancer - Google Patents
Method for detecting metastasis of GI cancer Download PDFInfo
- Publication number
- AU2010217160C1 AU2010217160C1 AU2010217160A AU2010217160A AU2010217160C1 AU 2010217160 C1 AU2010217160 C1 AU 2010217160C1 AU 2010217160 A AU2010217160 A AU 2010217160A AU 2010217160 A AU2010217160 A AU 2010217160A AU 2010217160 C1 AU2010217160 C1 AU 2010217160C1
- Authority
- AU
- Australia
- Prior art keywords
- gcc
- cancer
- gusb
- sample
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 238000000034 method Methods 0.000 title claims abstract description 181
- 206010027476 Metastases Diseases 0.000 title claims abstract description 31
- 206010028980 Neoplasm Diseases 0.000 title claims description 197
- 201000011510 cancer Diseases 0.000 title claims description 162
- 230000009401 metastasis Effects 0.000 title claims description 12
- 108010001687 Enterotoxin Receptors Proteins 0.000 claims abstract description 749
- 210000001165 lymph node Anatomy 0.000 claims abstract description 175
- 210000004027 cell Anatomy 0.000 claims abstract description 114
- 108020004999 messenger RNA Proteins 0.000 claims abstract description 87
- 206010009944 Colon cancer Diseases 0.000 claims abstract description 84
- 238000001514 detection method Methods 0.000 claims abstract description 65
- 238000011002 quantification Methods 0.000 claims abstract description 63
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims abstract description 57
- 230000004083 survival effect Effects 0.000 claims abstract description 28
- 102000053187 Glucuronidase Human genes 0.000 claims abstract description 21
- 108010060309 Glucuronidase Proteins 0.000 claims abstract description 21
- 238000011529 RT qPCR Methods 0.000 claims abstract description 17
- 238000012544 monitoring process Methods 0.000 claims abstract description 15
- 102000000820 Enterotoxin Receptors Human genes 0.000 claims abstract 78
- 238000003762 quantitative reverse transcription PCR Methods 0.000 claims abstract 7
- 102100026031 Beta-glucuronidase Human genes 0.000 claims description 246
- 239000000523 sample Substances 0.000 claims description 223
- 230000014509 gene expression Effects 0.000 claims description 125
- 210000001519 tissue Anatomy 0.000 claims description 89
- 238000011282 treatment Methods 0.000 claims description 35
- 210000004369 blood Anatomy 0.000 claims description 33
- 239000008280 blood Substances 0.000 claims description 33
- 210000002784 stomach Anatomy 0.000 claims description 27
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 23
- 101000933465 Homo sapiens Beta-glucuronidase Proteins 0.000 claims description 23
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 23
- 201000004101 esophageal cancer Diseases 0.000 claims description 23
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 23
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 23
- 102000040430 polynucleotide Human genes 0.000 claims description 23
- 108091033319 polynucleotide Proteins 0.000 claims description 23
- 239000002157 polynucleotide Substances 0.000 claims description 23
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 22
- 201000002528 pancreatic cancer Diseases 0.000 claims description 22
- 210000000813 small intestine Anatomy 0.000 claims description 22
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 21
- 206010017758 gastric cancer Diseases 0.000 claims description 21
- 201000011549 stomach cancer Diseases 0.000 claims description 21
- 230000000968 intestinal effect Effects 0.000 claims description 19
- 239000012807 PCR reagent Substances 0.000 claims description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 16
- 201000010099 disease Diseases 0.000 claims description 15
- 230000008901 benefit Effects 0.000 claims description 14
- 206010061819 Disease recurrence Diseases 0.000 claims description 10
- 239000003153 chemical reaction reagent Substances 0.000 claims description 9
- 201000002314 small intestine cancer Diseases 0.000 claims description 9
- 230000008859 change Effects 0.000 claims description 8
- 238000011226 adjuvant chemotherapy Methods 0.000 claims description 7
- 238000004364 calculation method Methods 0.000 claims description 5
- 238000001574 biopsy Methods 0.000 claims description 3
- 238000012790 confirmation Methods 0.000 claims description 3
- 238000010837 poor prognosis Methods 0.000 claims description 3
- 108090000623 proteins and genes Proteins 0.000 abstract description 172
- 238000003556 assay Methods 0.000 abstract description 141
- 208000029742 colonic neoplasm Diseases 0.000 abstract description 30
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract description 17
- 238000004393 prognosis Methods 0.000 abstract description 12
- 238000013517 stratification Methods 0.000 abstract description 11
- 210000000664 rectum Anatomy 0.000 abstract description 10
- 238000003757 reverse transcription PCR Methods 0.000 abstract description 10
- 210000001198 duodenum Anatomy 0.000 abstract description 7
- 238000005516 engineering process Methods 0.000 abstract description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 abstract description 2
- 210000002919 epithelial cell Anatomy 0.000 abstract description 2
- 102100022662 Guanylyl cyclase C Human genes 0.000 description 672
- 101000756632 Homo sapiens Actin, cytoplasmic 1 Proteins 0.000 description 114
- 238000012360 testing method Methods 0.000 description 87
- 238000006243 chemical reaction Methods 0.000 description 54
- 102100021699 Eukaryotic translation initiation factor 3 subunit B Human genes 0.000 description 40
- 101000896557 Homo sapiens Eukaryotic translation initiation factor 3 subunit B Proteins 0.000 description 40
- 101000988834 Homo sapiens Hypoxanthine-guanine phosphoribosyltransferase Proteins 0.000 description 40
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 34
- 238000006731 degradation reaction Methods 0.000 description 32
- 230000015556 catabolic process Effects 0.000 description 31
- 238000004458 analytical method Methods 0.000 description 30
- 230000002441 reversible effect Effects 0.000 description 30
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 27
- 210000001072 colon Anatomy 0.000 description 26
- 102100040296 TATA-box-binding protein Human genes 0.000 description 25
- 101710145783 TATA-box-binding protein Proteins 0.000 description 25
- 101710156592 Putative TATA-binding protein pB263R Proteins 0.000 description 24
- 241000239226 Scorpiones Species 0.000 description 24
- 208000027124 goblet cell carcinoma Diseases 0.000 description 24
- 238000003753 real-time PCR Methods 0.000 description 22
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 20
- 230000003321 amplification Effects 0.000 description 20
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 20
- 238000003199 nucleic acid amplification method Methods 0.000 description 20
- 102100028251 Phosphoglycerate kinase 1 Human genes 0.000 description 18
- 150000007523 nucleic acids Chemical class 0.000 description 18
- 101000579123 Homo sapiens Phosphoglycerate kinase 1 Proteins 0.000 description 17
- KJWZYMMLVHIVSU-IYCNHOCDSA-N PGK1 Chemical compound CCCCC[C@H](O)\C=C\[C@@H]1[C@@H](CCCCCCC(O)=O)C(=O)CC1=O KJWZYMMLVHIVSU-IYCNHOCDSA-N 0.000 description 17
- 102000039446 nucleic acids Human genes 0.000 description 17
- 108020004707 nucleic acids Proteins 0.000 description 17
- 230000035945 sensitivity Effects 0.000 description 16
- 108091093088 Amplicon Proteins 0.000 description 14
- 238000002474 experimental method Methods 0.000 description 14
- 238000010606 normalization Methods 0.000 description 14
- 230000034994 death Effects 0.000 description 13
- 231100000517 death Toxicity 0.000 description 13
- 230000000694 effects Effects 0.000 description 13
- 238000003745 diagnosis Methods 0.000 description 12
- 239000000463 material Substances 0.000 description 12
- 230000008569 process Effects 0.000 description 12
- 210000000056 organ Anatomy 0.000 description 11
- 210000003238 esophagus Anatomy 0.000 description 10
- 238000011156 evaluation Methods 0.000 description 10
- 238000002271 resection Methods 0.000 description 10
- 108020004414 DNA Proteins 0.000 description 9
- 238000013461 design Methods 0.000 description 9
- 239000000834 fixative Substances 0.000 description 9
- 239000002773 nucleotide Substances 0.000 description 9
- 125000003729 nucleotide group Chemical group 0.000 description 9
- 238000010839 reverse transcription Methods 0.000 description 9
- 239000003550 marker Substances 0.000 description 8
- 210000000496 pancreas Anatomy 0.000 description 8
- -1 GUSB Proteins 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 239000000284 extract Substances 0.000 description 7
- 210000004185 liver Anatomy 0.000 description 7
- 230000007170 pathology Effects 0.000 description 7
- 230000010473 stable expression Effects 0.000 description 7
- 238000003786 synthesis reaction Methods 0.000 description 7
- 238000013518 transcription Methods 0.000 description 7
- 230000035897 transcription Effects 0.000 description 7
- 239000013614 RNA sample Substances 0.000 description 6
- 239000013060 biological fluid Substances 0.000 description 6
- 238000000605 extraction Methods 0.000 description 6
- 239000012634 fragment Substances 0.000 description 6
- 238000013467 fragmentation Methods 0.000 description 6
- 238000006062 fragmentation reaction Methods 0.000 description 6
- 230000007062 hydrolysis Effects 0.000 description 6
- 238000006460 hydrolysis reaction Methods 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 230000000306 recurrent effect Effects 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 239000011547 Bouin solution Substances 0.000 description 5
- 208000005443 Circulating Neoplastic Cells Diseases 0.000 description 5
- 101000899808 Homo sapiens Guanylyl cyclase C Proteins 0.000 description 5
- 238000009015 Human TaqMan MicroRNA Assay kit Methods 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 238000005251 capillar electrophoresis Methods 0.000 description 5
- 239000002299 complementary DNA Substances 0.000 description 5
- 238000002405 diagnostic procedure Methods 0.000 description 5
- 210000000936 intestine Anatomy 0.000 description 5
- 210000004072 lung Anatomy 0.000 description 5
- 230000001394 metastastic effect Effects 0.000 description 5
- 206010061289 metastatic neoplasm Diseases 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 241000252983 Caecum Species 0.000 description 4
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 4
- 208000015634 Rectal Neoplasms Diseases 0.000 description 4
- 239000000090 biomarker Substances 0.000 description 4
- 210000001124 body fluid Anatomy 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 238000010804 cDNA synthesis Methods 0.000 description 4
- 210000004534 cecum Anatomy 0.000 description 4
- 230000000875 corresponding effect Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 210000004907 gland Anatomy 0.000 description 4
- 210000003405 ileum Anatomy 0.000 description 4
- 210000002429 large intestine Anatomy 0.000 description 4
- 210000002751 lymph Anatomy 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 208000037819 metastatic cancer Diseases 0.000 description 4
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 4
- 230000007935 neutral effect Effects 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 238000013207 serial dilution Methods 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 102100027314 Beta-2-microglobulin Human genes 0.000 description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 3
- 108700024394 Exon Proteins 0.000 description 3
- 102100034343 Integrase Human genes 0.000 description 3
- 102100034539 Peptidyl-prolyl cis-trans isomerase A Human genes 0.000 description 3
- 102100035367 Phosphomannomutase 1 Human genes 0.000 description 3
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 210000001815 ascending colon Anatomy 0.000 description 3
- 230000006399 behavior Effects 0.000 description 3
- 239000010839 body fluid Substances 0.000 description 3
- 238000011109 contamination Methods 0.000 description 3
- 230000002596 correlated effect Effects 0.000 description 3
- 210000001731 descending colon Anatomy 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 238000009396 hybridization Methods 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 208000020816 lung neoplasm Diseases 0.000 description 3
- 210000001672 ovary Anatomy 0.000 description 3
- 239000012188 paraffin wax Substances 0.000 description 3
- 238000004321 preservation Methods 0.000 description 3
- 210000002307 prostate Anatomy 0.000 description 3
- 206010038038 rectal cancer Diseases 0.000 description 3
- 201000001275 rectum cancer Diseases 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 210000001599 sigmoid colon Anatomy 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 210000001685 thyroid gland Anatomy 0.000 description 3
- 238000004448 titration Methods 0.000 description 3
- 210000003384 transverse colon Anatomy 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 210000002438 upper gastrointestinal tract Anatomy 0.000 description 3
- 210000003932 urinary bladder Anatomy 0.000 description 3
- 102000007469 Actins Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- 208000003174 Brain Neoplasms Diseases 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 102100028472 DNA-directed RNA polymerases I, II, and III subunit RPABC5 Human genes 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 2
- 101000723805 Homo sapiens DNA-directed RNA polymerases I, II, and III subunit RPABC5 Proteins 0.000 description 2
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 2
- 101001067833 Homo sapiens Peptidyl-prolyl cis-trans isomerase A Proteins 0.000 description 2
- 101001094827 Homo sapiens Phosphomannomutase 1 Proteins 0.000 description 2
- 101000735893 Homo sapiens Proteasome subunit beta type-6 Proteins 0.000 description 2
- 238000010824 Kaplan-Meier survival analysis Methods 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 238000002944 PCR assay Methods 0.000 description 2
- 102100037935 Polyubiquitin-C Human genes 0.000 description 2
- 206010036790 Productive cough Diseases 0.000 description 2
- 102100036128 Proteasome subunit beta type-6 Human genes 0.000 description 2
- 230000021839 RNA stabilization Effects 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 208000009956 adenocarcinoma Diseases 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 238000009098 adjuvant therapy Methods 0.000 description 2
- 238000002820 assay format Methods 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 238000011088 calibration curve Methods 0.000 description 2
- 230000005773 cancer-related death Effects 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 238000013211 curve analysis Methods 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 2
- 238000013213 extrapolation Methods 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 210000000232 gallbladder Anatomy 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 238000001325 log-rank test Methods 0.000 description 2
- 210000003750 lower gastrointestinal tract Anatomy 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 238000009099 neoadjuvant therapy Methods 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 210000000582 semen Anatomy 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 210000003802 sputum Anatomy 0.000 description 2
- 208000024794 sputum Diseases 0.000 description 2
- 230000036962 time dependent Effects 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- YRIZYWQGELRKNT-UHFFFAOYSA-N 1,3,5-trichloro-1,3,5-triazinane-2,4,6-trione Chemical compound ClN1C(=O)N(Cl)C(=O)N(Cl)C1=O YRIZYWQGELRKNT-UHFFFAOYSA-N 0.000 description 1
- AQQSXKSWTNWXKR-UHFFFAOYSA-N 2-(2-phenylphenanthro[9,10-d]imidazol-3-yl)acetic acid Chemical compound C1(=CC=CC=C1)C1=NC2=C(N1CC(=O)O)C1=CC=CC=C1C=1C=CC=CC=12 AQQSXKSWTNWXKR-UHFFFAOYSA-N 0.000 description 1
- VUFNLQXQSDUXKB-DOFZRALJSA-N 2-[4-[4-[bis(2-chloroethyl)amino]phenyl]butanoyloxy]ethyl (5z,8z,11z,14z)-icosa-5,8,11,14-tetraenoate Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)OCCOC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 VUFNLQXQSDUXKB-DOFZRALJSA-N 0.000 description 1
- 101150087690 ACTB gene Proteins 0.000 description 1
- 208000003200 Adenoma Diseases 0.000 description 1
- 206010001233 Adenoma benign Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108010083123 CDX2 Transcription Factor Proteins 0.000 description 1
- 102000006277 CDX2 Transcription Factor Human genes 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 208000006478 Cecal Neoplasms Diseases 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 206010055114 Colon cancer metastatic Diseases 0.000 description 1
- 206010052358 Colorectal cancer metastatic Diseases 0.000 description 1
- 108010072220 Cyclophilin A Proteins 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 206010014967 Ependymoma Diseases 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 206010017969 Gastrointestinal inflammatory conditions Diseases 0.000 description 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 101710111502 Heat-stable enterotoxin ST Proteins 0.000 description 1
- 206010019695 Hepatic neoplasm Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101100215371 Homo sapiens ACTB gene Proteins 0.000 description 1
- 101000937544 Homo sapiens Beta-2-microglobulin Proteins 0.000 description 1
- 101000662049 Homo sapiens Polyubiquitin-C Proteins 0.000 description 1
- 101000706678 Homo sapiens Proteasome subunit beta type-1 Proteins 0.000 description 1
- 101000595252 Homo sapiens Serine/threonine-protein phosphatase PP1-alpha catalytic subunit Proteins 0.000 description 1
- 101000653679 Homo sapiens Translationally-controlled tumor protein Proteins 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 208000005016 Intestinal Neoplasms Diseases 0.000 description 1
- FSNCEEGOMTYXKY-JTQLQIEISA-N Lycoperodine 1 Natural products N1C2=CC=CC=C2C2=C1CN[C@H](C(=O)O)C2 FSNCEEGOMTYXKY-JTQLQIEISA-N 0.000 description 1
- 208000007433 Lymphatic Metastasis Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010027459 Metastases to lymph nodes Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000751119 Mila <angiosperm> Species 0.000 description 1
- ZBZXYUYUUDZCNB-UHFFFAOYSA-N N-cyclohexa-1,3-dien-1-yl-N-phenyl-4-[4-(N-[4-[4-(N-[4-[4-(N-phenylanilino)phenyl]phenyl]anilino)phenyl]phenyl]anilino)phenyl]aniline Chemical compound C1=CCCC(N(C=2C=CC=CC=2)C=2C=CC(=CC=2)C=2C=CC(=CC=2)N(C=2C=CC=CC=2)C=2C=CC(=CC=2)C=2C=CC(=CC=2)N(C=2C=CC=CC=2)C=2C=CC(=CC=2)C=2C=CC(=CC=2)N(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 ZBZXYUYUUDZCNB-UHFFFAOYSA-N 0.000 description 1
- 208000003788 Neoplasm Micrometastasis Diseases 0.000 description 1
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 101710139464 Phosphoglycerate kinase 1 Proteins 0.000 description 1
- 101710133556 Phosphomannomutase 1 Proteins 0.000 description 1
- 102100031566 Proteasome subunit beta type-1 Human genes 0.000 description 1
- 102000017143 RNA Polymerase I Human genes 0.000 description 1
- 108010013845 RNA Polymerase I Proteins 0.000 description 1
- 108010000605 Ribosomal Proteins Proteins 0.000 description 1
- 102000002278 Ribosomal Proteins Human genes 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 208000003837 Second Primary Neoplasms Diseases 0.000 description 1
- 102100036033 Serine/threonine-protein phosphatase PP1-alpha catalytic subunit Human genes 0.000 description 1
- 208000009125 Sigmoid Neoplasms Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 102100026144 Transferrin receptor protein 1 Human genes 0.000 description 1
- 102100029887 Translationally-controlled tumor protein Human genes 0.000 description 1
- 102000044159 Ubiquitin Human genes 0.000 description 1
- 108090000848 Ubiquitin Proteins 0.000 description 1
- 238000011353 adjuvant radiotherapy Methods 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- FFBHFFJDDLITSX-UHFFFAOYSA-N benzyl N-[2-hydroxy-4-(3-oxomorpholin-4-yl)phenyl]carbamate Chemical compound OC1=C(NC(=O)OCC2=CC=CC=C2)C=CC(=C1)N1CCOCC1=O FFBHFFJDDLITSX-UHFFFAOYSA-N 0.000 description 1
- 210000000013 bile duct Anatomy 0.000 description 1
- 230000008436 biogenesis Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000001851 biosynthetic effect Effects 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000003040 circulating cell Anatomy 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 238000012864 cross contamination Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 238000011498 curative surgery Methods 0.000 description 1
- 210000004292 cytoskeleton Anatomy 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 210000000188 diaphragm Anatomy 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 125000003700 epoxy group Chemical group 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 239000012520 frozen sample Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000003633 gene expression assay Methods 0.000 description 1
- 238000011223 gene expression profiling Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000034659 glycolysis Effects 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 230000003118 histopathologic effect Effects 0.000 description 1
- 238000007489 histopathology method Methods 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000001630 jejunum Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 238000007834 ligase chain reaction Methods 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 208000037841 lung tumor Diseases 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 208000017708 myomatous neoplasm Diseases 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 239000002853 nucleic acid probe Substances 0.000 description 1
- 238000001821 nucleic acid purification Methods 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical compound OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 101150038183 pmm1 gene Proteins 0.000 description 1
- 229920000647 polyepoxide Polymers 0.000 description 1
- 229920013617 polymethylmethyacrylimide Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000012846 protein folding Effects 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 208000013718 rectal benign neoplasm Diseases 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 210000003079 salivary gland Anatomy 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 238000012420 spiking experiment Methods 0.000 description 1
- 208000021550 spleen neoplasm Diseases 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 210000004876 tela submucosa Anatomy 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- ZSDSQXJSNMTJDA-UHFFFAOYSA-N trifluralin Chemical compound CCCN(CCC)C1=C([N+]([O-])=O)C=C(C(F)(F)F)C=C1[N+]([O-])=O ZSDSQXJSNMTJDA-UHFFFAOYSA-N 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 210000000504 visceral peritoneum Anatomy 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57419—Specifically defined cancers of colon
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/527—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving lyase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Urology & Nephrology (AREA)
- Analytical Chemistry (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15517209P | 2009-02-25 | 2009-02-25 | |
| US61/155,172 | 2009-02-25 | ||
| US24619709P | 2009-09-28 | 2009-09-28 | |
| US61/246,197 | 2009-09-28 | ||
| PCT/CA2010/000277 WO2010096929A1 (en) | 2009-02-25 | 2010-02-24 | Method for detecting metastasis of gi cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| AU2010217160A1 AU2010217160A1 (en) | 2011-09-22 |
| AU2010217160B2 AU2010217160B2 (en) | 2014-11-20 |
| AU2010217160C1 true AU2010217160C1 (en) | 2015-07-02 |
Family
ID=42664977
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2010217160A Ceased AU2010217160C1 (en) | 2009-02-25 | 2010-02-24 | Method for detecting metastasis of GI cancer |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20110306055A1 (enExample) |
| EP (2) | EP2401394B1 (enExample) |
| JP (1) | JP2012518389A (enExample) |
| CN (1) | CN102333887B (enExample) |
| AU (1) | AU2010217160C1 (enExample) |
| CA (1) | CA2752668A1 (enExample) |
| WO (1) | WO2010096929A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011050242A1 (en) | 2009-10-23 | 2011-04-28 | Millennium Pharmaceuticals, Inc. | Anti-gcc antibody molecules and related compositions and methods |
| US9416410B2 (en) * | 2012-02-14 | 2016-08-16 | Genetics Development Corporation | Cutoff point delta Ct. method for HER2 PCR testing in breast cancer |
| EP2841575B1 (en) | 2012-04-27 | 2019-06-26 | Millennium Pharmaceuticals, Inc. | Anti-gcc antibody molecules and use of same to test for susceptibility to gcc-targeted therapy |
| WO2016028141A1 (en) * | 2014-08-18 | 2016-02-25 | Universiti Kebangsaan Malaysia | Method for determining prognosis of colorectal cancer |
| AU2015319850B2 (en) | 2014-09-25 | 2019-09-26 | Bt Bidco, Inc. | Electromechanical pill device with localization capabilities |
| CA3034267A1 (en) * | 2016-08-18 | 2018-02-22 | Mitchell Lawrence Jones | Systems for obtaining samples using ingestible devices |
| US20180070857A1 (en) | 2016-09-09 | 2018-03-15 | Progenity Inc. | Electromechanical ingestible device for delivery of a dispensable substance |
| EP3551047A1 (en) | 2016-12-07 | 2019-10-16 | Progenity, Inc. | Gastrointestinal tract detection methods, devices and systems |
| US11761032B2 (en) * | 2017-03-11 | 2023-09-19 | Yan Wang | Methods and devices for performing real time digital PCR |
| EP3900613B1 (en) | 2017-03-31 | 2023-12-27 | Biora Therapeutics, Inc. | Localization methods for an ingestible device |
| CN116726362A (zh) | 2018-11-19 | 2023-09-12 | 比奥拉治疗股份有限公司 | 用生物治疗剂治疗疾病的方法和装置 |
| CN110819715A (zh) * | 2019-11-26 | 2020-02-21 | 华夏帮服科技有限公司 | 用于结直肠癌检测的免疫基因标志物及试剂盒 |
| CN118460719A (zh) * | 2020-03-02 | 2024-08-09 | 腾辰生物科技(上海)有限公司 | 一种分子标志物及试剂盒在辅助诊断食管癌中的应用 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008045133A2 (en) * | 2006-03-03 | 2008-04-17 | Veridex, Llc | Molecular assay to predict recurrence of dukes' b colon cancer |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4194113B2 (ja) | 1993-10-26 | 2008-12-10 | トーマス・ジェファーソン・ユニバーシティ | 結腸直腸癌細胞に特異的に結合する組成物およびその使用方法 |
| US5601990A (en) | 1994-09-13 | 1997-02-11 | Thomas Jefferson University | Methods of diagnosing colorectal tumors and metastasis thereof |
| US6602659B1 (en) | 1996-05-03 | 2003-08-05 | Thomas Jefferson University | Methods of and kits and compositions for diagnosing colorectal tumors and metastasis thereof |
| US6120995A (en) | 1997-08-07 | 2000-09-19 | Thomas Jefferson University | Compositions that specifically bind to colorectal cancer cells and methods of using the same |
| US7135333B1 (en) | 1997-08-07 | 2006-11-14 | Thomas Jefferson University | Compositions that specifically bind to colorectal cancer cells and methods of using the same |
| US6844153B2 (en) | 2000-03-27 | 2005-01-18 | Thomas Jefferson University | Compositions and methods for identifying and targeting cancer cells of alimentary canal origin |
| US7138226B2 (en) | 2002-05-10 | 2006-11-21 | The University Of Miami | Preservation of RNA and morphology in cells and tissues |
| US20040018494A1 (en) * | 2002-07-25 | 2004-01-29 | Shurtliff Roxanne N | Isothermal transcription based amplification assay for detection and quantification of guanylyl cyclase C |
| DE102004024617A1 (de) * | 2004-05-18 | 2005-12-29 | Ganymed Pharmaceuticals Ag | Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung |
-
2010
- 2010-02-24 CA CA2752668A patent/CA2752668A1/en not_active Abandoned
- 2010-02-24 CN CN201080009215.XA patent/CN102333887B/zh not_active Expired - Fee Related
- 2010-02-24 EP EP10745780.6A patent/EP2401394B1/en not_active Not-in-force
- 2010-02-24 AU AU2010217160A patent/AU2010217160C1/en not_active Ceased
- 2010-02-24 EP EP13185224.6A patent/EP2677036A3/en not_active Withdrawn
- 2010-02-24 JP JP2011550395A patent/JP2012518389A/ja active Pending
- 2010-02-24 WO PCT/CA2010/000277 patent/WO2010096929A1/en not_active Ceased
- 2010-02-24 US US12/935,201 patent/US20110306055A1/en not_active Abandoned
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008045133A2 (en) * | 2006-03-03 | 2008-04-17 | Veridex, Llc | Molecular assay to predict recurrence of dukes' b colon cancer |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2010096929A1 (en) | 2010-09-02 |
| CN102333887A (zh) | 2012-01-25 |
| EP2401394A1 (en) | 2012-01-04 |
| HK1165836A1 (en) | 2012-10-12 |
| AU2010217160A1 (en) | 2011-09-22 |
| EP2401394A4 (en) | 2012-07-11 |
| US20110306055A1 (en) | 2011-12-15 |
| AU2010217160B2 (en) | 2014-11-20 |
| JP2012518389A (ja) | 2012-08-16 |
| CA2752668A1 (en) | 2010-09-02 |
| EP2401394B1 (en) | 2013-11-27 |
| EP2677036A2 (en) | 2013-12-25 |
| CN102333887B (zh) | 2014-04-02 |
| EP2677036A3 (en) | 2014-01-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2010217160C1 (en) | Method for detecting metastasis of GI cancer | |
| US10494677B2 (en) | Predicting cancer outcome | |
| ES2812105T3 (es) | Algoritmo y evaluación del perfil de expresión génica para determinar el pronóstico del cáncer de próstata | |
| ES2741745T3 (es) | Método para usar la expresión génica para determinar el pronóstico de cáncer de próstata | |
| Kanda et al. | The expression of melanoma-associated antigen D2 both in surgically resected and serum samples serves as clinically relevant biomarker of gastric cancer progression | |
| US20110152113A1 (en) | Genomic fingerprint of breast cancer | |
| Bournet et al. | Gene expression signature of advanced pancreatic ductal adenocarcinoma using low density array on endoscopic ultrasound-guided fine needle aspiration samples | |
| ES2914727T3 (es) | Algoritmos y métodos para evaluar los criterios clínicos tardíos en el cáncer de próstata | |
| US9606122B2 (en) | Prognosis of oesophageal and gastro-oesophageal junctional cancer | |
| US20130303400A1 (en) | Multimarker panel | |
| KR102036222B1 (ko) | 당뇨병성 신증에 의한 만성신장질환 환자의 예후 예측용 마커 | |
| CA2760050A1 (en) | Guanylyl cyclase c qrt-pcr | |
| Labuhn et al. | Simultaneous quantitative detection of relevant biomarkers in breast cancer by quantitative real-time PCR | |
| AU2009216723B2 (en) | BRCA1 mRNA expression predicts survival in patients with bladder cancer treated with neoadjuvant cisplatin-based chemotherapy | |
| HK1165836B (en) | Method for detecting metastasis of gi cancer | |
| US7358060B2 (en) | Method for monitoring and prognosis of disease course of gastrointestinal tumors | |
| KR102036219B1 (ko) | 유전자 프로모터의 CpG 메틸화 변화를 이용한 만성신장질환의 악화 예측용 조성물 및 이의 이용 | |
| KR102036220B1 (ko) | 만성신장질환 특이적 후성학적 메틸화 마커 검출용 조성물 및 검출방법 | |
| KR102036221B1 (ko) | 만성신장질환의 예후 예측을 위한 후성 유전학적 진단 키트 개발 | |
| Troyer et al. | Quantitation of TMPRSS2: ERG fusion transcripts in frozen and paraffin embedded prostate cancers (PC) | |
| KR20170012816A (ko) | Cirp 유전자의 발현 수준을 측정하는 제제를 포함하는 대장암 예후 예측용 조성물 | |
| EP2212433A2 (en) | Ptpl1 as a biomaker of survival in breast cancer. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| DA2 | Applications for amendment section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 09 FEB 2015 . |
|
| DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 09 FEB 2015 |
|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |